UF startup Sun BioPharma, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, announced leadership changes in the organization.
David B. Kaysen is stepping down as President, CEO and Board member of Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd. Michael T. Cullen, MD, MBA, the company’s Executive Chairman, has accepted the additional responsibilities of President and CEO of Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd.
These changes are a result of the need for cost reductions to focus further spending on the current Phase 1a/1b clinical trial in the front-line combination study of SBP-101 with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. Mr. Kaysen departs in good standing with the Company and has agreed to act as a consultant to Sun BioPharma to provide advice and continuity on various matters.
Learn more about Sun BioPharma Announces Leadership Changes.